Charmaine B Jensen, DO in Lincolnville, ME - Surgery

Charmaine B Jensen, DO is a Surgery - Plastic And Reconstructive Surgery physician based in Lincolnville, Maine. Charmaine B Jensen is licensed to practice in Maine (license number 1822) and her current practice location is 2239 Atlantic Hwy, Lincolnville, Maine. She can be reached at her office (for appointments etc.) via phone at (207) 230-1007.

NPI number for Charmaine B Jensen is 1215010889 and her current mailing address is 2239 Atlantic Hwy, Lincolnville, Maine. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1215010889.

Contact Information

	Charmaine B Jensen, DO
	2239 Atlantic Hwy, Lincolnville, ME 04849-5310
	(207) 230-1007
	(207) 230-1008

Physician's Profile

Full Name	Charmaine B Jensen
Gender	Female
Speciality	Surgery - Plastic And Reconstructive Surgery
Location	2239 Atlantic Hwy, Lincolnville, Maine
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1215010889
Provider Enumeration Date: 10/24/2006
Last Update Date: 01/28/2013

Medical Identifiers

Medical identifiers for Charmaine B Jensen such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1215010889	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2086S0122X	Surgery - Plastic And Reconstructive Surgery	1822 (Maine)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Charmaine B Jensen is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Charmaine B Jensen, DO 2239 Atlantic Hwy, Lincolnville, ME 04849-5310 Ph: (207) 230-1007	Charmaine B Jensen, DO 2239 Atlantic Hwy, Lincolnville, ME 04849-5310 Ph: (207) 230-1007

News Archive

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.

NHS: a health service or an illness service? An interview with Dr Paula Crick

I've been a nurse for almost 32 years and one of the things that has always been difficult for me to comprehend is that all too often we treat people who are sick, having missed opportunities to prevent, screen or intervene.

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

OCC members praise FDA approval of new obesity drug – Belviq

Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.

Charmaine B Jensen, DO - Surgery in Lincolnville, ME